CRIS Current Research Information System

MOLLICA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.486
NA - Nord America 4.477
EU - Europa 2.713
SA - Sud America 420
Continente sconosciuto - Info sul continente non disponibili 364
AF - Africa 344
OC - Oceania 8
Totale 15.812
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.318
SG - Singapore 2.254
CN - Cina 2.041
VN - Vietnam 1.468
IT - Italia 887
HK - Hong Kong 550
KR - Corea 401
BR - Brasile 309
DE - Germania 279
SE - Svezia 268
IN - India 237
NL - Olanda 222
GB - Regno Unito 204
FR - Francia 163
FI - Finlandia 146
BD - Bangladesh 135
CH - Svizzera 117
CI - Costa d'Avorio 113
SC - Seychelles 111
RU - Federazione Russa 107
JP - Giappone 101
IE - Irlanda 97
CA - Canada 86
PH - Filippine 48
AR - Argentina 45
BG - Bulgaria 45
ID - Indonesia 44
ZA - Sudafrica 41
PL - Polonia 38
JO - Giordania 33
MX - Messico 33
AT - Austria 31
TH - Thailandia 30
ES - Italia 29
TG - Togo 29
TR - Turchia 27
PK - Pakistan 19
IQ - Iraq 16
CL - Cile 14
TW - Taiwan 14
UA - Ucraina 14
CO - Colombia 12
VE - Venezuela 12
JM - Giamaica 11
LT - Lituania 10
UZ - Uzbekistan 10
EC - Ecuador 9
EG - Egitto 9
MY - Malesia 9
NG - Nigeria 9
PT - Portogallo 8
SA - Arabia Saudita 8
PE - Perù 7
AU - Australia 6
BE - Belgio 6
KZ - Kazakistan 6
NI - Nicaragua 6
PY - Paraguay 6
HR - Croazia 5
HU - Ungheria 5
KE - Kenya 5
RO - Romania 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CR - Costa Rica 4
GR - Grecia 4
IL - Israele 4
PS - Palestinian Territory 4
TN - Tunisia 4
AL - Albania 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EE - Estonia 3
GH - Ghana 3
GT - Guatemala 3
IR - Iran 3
NP - Nepal 3
OM - Oman 3
PR - Porto Rico 3
RS - Serbia 3
CD - Congo 2
CY - Cipro 2
ET - Etiopia 2
HN - Honduras 2
KG - Kirghizistan 2
LB - Libano 2
MA - Marocco 2
MK - Macedonia 2
ML - Mali 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
BW - Botswana 1
Totale 15.429
Salva come PNG Salva come JPEG
Città #
Singapore 1.566
Hefei 795
Ashburn 571
Hong Kong 516
Ho Chi Minh City 408
San Jose 392
Seoul 376
Hanoi 343
Santa Clara 256
Beijing 223
Boardman 220
Bologna 180
Chandler 168
Los Angeles 157
Council Bluffs 140
Helsinki 115
Milan 114
Abidjan 113
Bern 111
Fairfield 109
Southend 107
Dallas 96
New York 96
Dublin 95
Buffalo 78
Tokyo 76
Bengaluru 73
Lauterbourg 72
Princeton 61
Da Nang 59
Houston 56
Seattle 56
Redondo Beach 55
Turin 49
Frankfurt am Main 47
São Paulo 46
Guangzhou 44
Haiphong 43
Sofia 42
Chicago 40
Woodbridge 40
Nuremberg 39
Cambridge 38
Wilmington 38
Rome 36
Shanghai 34
Amman 33
Boydton 33
Phoenix 32
Lomé 29
Munich 29
Dong Ket 28
Tongling 28
Jakarta 26
Johannesburg 25
Montreal 25
Ann Arbor 24
Brooklyn 24
Warsaw 24
Denver 23
Florence 23
Lappeenranta 22
Amsterdam 21
London 21
Paris 21
San Francisco 21
Atlanta 20
Orem 20
Redmond 20
Vienna 20
Berlin 19
Falkenstein 19
Toronto 19
Biên Hòa 18
Hyderabad 16
Hải Dương 16
Shenzhen 16
Can Tho 14
Moscow 14
Stockholm 14
Zhengzhou 14
Boston 13
Des Moines 13
Nanjing 13
Tianjin 13
Xi'an 13
Changsha 12
Charlotte 12
Mexico City 12
Quận Bình Thạnh 12
Redwood City 12
Bari 11
Bühl 11
Jinan 11
Verona 11
Bangkok 10
Castel Maggiore 10
Hangzhou 10
Ninh Bình 10
Quận Ba 10
Totale 9.379
Salva come PNG Salva come JPEG
Nome #
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 305
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 270
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 244
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 234
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 231
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 225
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 218
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 210
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 204
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 203
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 187
Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma 182
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 180
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 177
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 177
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 174
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 173
Bone targeting agents in patients with metastatic prostate cancer: State of the art 169
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 168
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 168
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 165
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 160
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 159
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 157
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 156
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 156
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 154
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 153
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 152
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 151
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 150
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 149
The human microbiota and prostate cancer: Friend or foe? 146
Is There a Role for Immunotherapy in Prostate Cancer? 143
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 142
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 138
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 138
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 137
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 132
Belzutifan: enhancing the blockade of angiogenesis in renal cell carcinoma 130
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 130
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 128
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 127
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 126
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 125
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 125
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 124
The functioning side of the pancreas: a review on insulinomas 123
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 122
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 121
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 115
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 114
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 112
Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer 111
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 111
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 111
Metabolomic profiling in renal cell carcinoma patients: News and views 110
SOX2 and PRAME in the "reprogramming" of seminoma cells 109
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 108
Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study 105
Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives 102
Role of Clock Genes and Circadian Rhythm in Renal Cell Carcinoma: Recent Evidence and Therapeutic Consequences 102
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 102
Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma 101
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 100
Effect on outcomes of toxicity-related dose reduction in TKI monotherapy or TKI-IO combination therapy for advanced renal cell carcinoma 99
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 99
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 99
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 99
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 99
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 97
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 96
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 95
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 95
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 93
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 92
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 87
Immunohistochemical expression of Nectin-4 and potential implications for enfortumab vedotin therapy in germ cell tumors of the testis: a preliminary study 86
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 86
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 85
Treating prostate cancer by antibody-drug conjugates 84
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 83
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 83
Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis 82
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 82
Immunophenotypical assessment supports that post-chemotherapy glandular tumours of germ cell origin straddle between glandular yolk sac tumour and ‘somatic-type’ adenocarcinoma 82
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 79
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 79
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 78
Pembrolizumab plus enfortumab vedotin in urothelial cancer 78
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 78
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 77
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 77
Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis 76
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 75
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 74
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 74
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 73
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 73
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 73
Totale 12.898
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.586
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022525 0 15 16 36 38 22 33 62 65 25 144 69
2022/20231.438 58 99 44 82 132 179 93 94 239 55 158 205
2023/2024753 87 96 64 65 51 100 22 78 40 57 46 47
2024/20253.521 149 429 312 222 417 145 236 159 64 254 406 728
2025/20268.521 909 1.182 904 744 819 305 773 236 1.317 622 412 298
2026/2027437 281 156 0 0 0 0 0 0 0 0 0 0
Totale 15.812